The Roche way: Spark found a new owner who wants to buy and build a gene therapy leader
For Roche, buying Spark $ONCE for $4.3 billion was just the beginning of a major foray into gene therapies. Now the pharma giant plans to build a new wing of the company around it.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
